Best Podcasts for Pharmaceutical Professionals: Top 3 Podcasts for Pharma and Biotech Insights
Staying on top of the latest trends in pharma and biotech is key if you’re in the generic drug industry. This month, we’re highlighting three podcasts that dive into the topics that matter most, from supply chain strategies to patent expirations and regulatory shifts. If you’re looking for practical insights and industry news, these podcasts offer great updates and conversations to help you keep up with the constantly evolving landscape.
1. Molecule to Market: Inside the Outsourcing Space
This podcast, hosted by Raman Sehgal, founder of life sciences marketing agency Ramarketing, zeroes in on the pharmaceutical and biotech contract outsourcing space. The show features in-depth interviews with industry leaders across the board, from contract research to development, manufacturing, logistics, and technology. Through Raman’s interviews, guests reveal emerging trends, industry challenges (and promising solutions), leadership strategies, and their career journeys. It’s a good listen for anyone involved in pharma outsourcing and the broader drug development landscape.
Check Out This Relevant Episode:
Title: "The pharma ingredients disruptor"
Guest: Jack Stine, CEO of Savendor
Overview: Jack discusses his experience with 3M's 70 supply chain teams and the shift towards sourcing APIs and excipients for generics under FDA regulations. He shares insights on secondary sourcing trends and his journey in founding Savendor, which aims to streamline pharma sourcing by reducing intermediaries.
Key Takeaways:
Secondary sourcing requires a deliberate, long-term strategy to mitigate supply chain disruption risks. This approach can improve resilience and continuity, which is especially crucial for generic pharmaceutical manufacturers who require consistent access to APIs and excipients.
One tactic Jack’s company uses to simplify sourcing is reducing intermediaries between manufacturers and suppliers. Prioritizing direct connections facilitates faster decision-making, improves transparency, and enhances efficiency—vital elements for competitive generics companies.
Check Out This Relevant Episode:
Title: "The Stickability factor"
Guest: Professor Tom Moody, Vice President of Technology Development and Commercialisation at Almac, a research-driven drug discovery company
Overview: Prof. Moody shares Almac’s approach to innovation in pharmaceutical manufacturing, focusing on strategies that support long-term success and efficiency. He highlights the importance of continuous process optimization, technology adaptation, and proactive regulatory alignment.
Key Takeaways:
Investing continuously in process development and optimization is critical for improving product quality and operational efficiency in generic pharmaceutical manufacturing.
Strong, collaborative relationships with partners help drive innovation and long-term growth across the supply chain.
Proactively adapting to regulatory changes safeguards product integrity and helps avoid costly delays or disruptions.
2. The Top Line
Alongside host Andrea Park, The Top Line podcast brings in journalists from Fierce Pharma, the pharma industry’s daily monitor, to review the latest industry trends and dig into why they matter. Every Friday morning, a new episode drops with the biggest business news. Think of it as your weekly news digest in short, digestible, audio format.
Check Out This Relevant Episode:
Title: "A closer look at pharma’s top patent losses in 2025”
Guests: Fierce Journalists Eric Sagonowsky and Angus Liu
Overview: This episode reviews the latest edition of Fierce Pharma’s annual special report, documenting the biggest losses of US exclusivity expected throughout 2025. It covers the stories behind 10 key medicines that will soon face generic and biosimilar competitors as their patent expires and discusses the effects of this year’s significant patent cliff.
Key Takeaways:
A whopping $26 billion in US pharmaceutical sales will be up for generic or biosimilar competition this year as many blockbusters see their patents expire.
Johnson & Johnson’s Stelara, which saw $6.7 billion in US sales last year, is the top drug facing patent expiration in 2205. This will be the most significant US loss of exclusivity since Humira went off the patent cliff in 2023.
3. PharmaSource Podcast
Brought to you by Life Science Network’s Co-Founder Luke Bilton, the PharmaSource podcast explores strategies to optimize partnerships, accelerate drug development, and advance sustainability in the pharmaceutical industry. Each episode features conversations with industry leaders on topics like building smarter, more sustainable supply chains, partnering with CDMOs, embracing digital transformation, and refining procurement strategies. Tailored for professionals in pharma and biotech, PharmaSource releases new episodes every few days to keep you in the loop.
Check Out This Relevant Episode:
Title: "US Pharma Manufacturing’s Perfect Storm: Trade Wars, FDA Shake-Ups, and BIOSECURE Legislation"
Guest: Gil Roth, President of the Pharma and Biopharma Outsourcing Association (PBOA)
Overview: Gil Roth discusses the challenges and changes in the US pharmaceutical manufacturing landscape, highlighting the impact of FDA changes, trade policies, and mergers and acquisitions on generic drug manufacturing.
Key Takeaways:
Gil emphasizes that stable leadership at the FDA is essential for keeping drug approvals on track, especially since over half of the FDA’s budget comes from user fees tied to industry timelines. Changes at the top could disrupt these agreements and slow down approvals, which would directly affect generic manufacturers.
He notes a spike in pharma mergers as companies try to adapt to market and regulatory shifts. This consolidation could reduce competition, shift manufacturing priorities, and potentially limit access to some generic drugs.
Keep Learning, Keep Growing
These podcasts provide valuable perspectives on the pharmaceutical industry’s current and future trends. Do you have a favorite podcast that you think we should check out or highlight? Let us know—we’re always looking for new recommendations.
